Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis
12. November 2024 07:00 ET
|
Attralus, Inc
NAPLES, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with...
Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
05. August 2024 07:00 ET
|
Attralus, Inc
124I-evuzamitide (AT-01) is one of the first investigational diagnostic imaging agents to receive Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA), and the only...
Attralus Receives European Medicines Agency Committee for Orphan Medicinal Products (COMP) Positive Opinions for AT-02 for the Treatment of Both ATTR and AL Amyloidosis
29. Juli 2024 07:00 ET
|
Attralus, Inc
AT-02 has been granted COMP positive opinions for orphan medicinal product designations in the EU for both ATTR and AL amyloidosisAT-02 is the Company’s lead pan-amyloid removal therapeutic candidate...
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
30. Mai 2024 07:00 ET
|
Attralus, Inc
AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis...
Attralus Closes $56 Million Financing
06. Februar 2024 07:00 ET
|
Attralus, Inc
Attralus, Inc. today announced that it has closed a $56 million financing.
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
07. November 2023 07:00 ET
|
Attralus, Inc
124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies.124I-evuzamitide detects multiple types of systemic...
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology
02. Oktober 2023 07:00 ET
|
Attralus, Inc
Attralus announced eight data presentations related to the use of 124I-evuzamitide (AT-01), the company's pan-amyloid binding imaging agent, at ASNC 2023.
Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
03. April 2023 07:00 ET
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis
19. Dezember 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
17. November 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...